April 1, 2021 -- Charles River Laboratories has paid approximately $48 million U.S. to acquire the U.K.-based contract research organization Retrogenix.
The acquisition strengthens Charles River's expertise with the addition of cell microarray technology and off-target screening for preclinical safety assurance in chimeric antigen receptor (CAR) T-cell therapies. Retrogenix's cell microarray technology can identify specific cell surface and secreted protein interactions in human cells, the firm said.
A potential additional payment of up to $7 million for future performance is included in the deal.
Copyright © 2021 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
